EGFR/VEGFR2-IN-5

EGFR/VEGFR2-IN-5 (Compound 14) is an orally bioavailable dual inhibitor targeting EGFR (T790M mutant, IC50=0.28 μM) and VEGFR2 (IC50=1.15 μM) . It demonstrates potent antitumor efficacy in preclinical studies, supporting its investigation in oncology research for cancers driven by EGFR mutations and angiogenesis.